They now have a $150.00 price target on the biopharmaceutical company’s stock. The stock was sold at an average price of $110.00, for a total value of $11,000,000.00. Following the completion of the sale, the director now owns 42,919 shares of the company’s stock, valued at $4,897,057.90. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Advertisement
Sell-side analysts are giving a thumbs-up to the stocks of Celgene Corporation (NASDAQ:CELG). The stock price is trading upbeat from its 200 days moving average with 4.17% and up from 50 days moving average with 4.03%.
Other institutional investors recently modified their holdings of the company. For the quarter, shares are performing at 9.94%. One week ago, shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “14” brokerage firms. Greenwood Capital Associates LLC raised its position in shares of Celgene Corp.by 5.2% in the fourth quarter. Succeeding to the transaction Hugin Robert owned overall 1,022,201 shares of the stock. Carmignac Gestion raised its stake in shares of Celgene Corp.by 28.1% in the second quarter. BTIG Research reiterated a “buy” rating and issued a $138.00 target price on shares of Celgene Corp.in a research note on Sunday. Vetr upgraded Celgene Corp. from a “hold” rating to a “buy” rating and set a $115.99 target price on the stock in a research note on Wednesday. Celgene Corporation makes up approx 0.04% of Harel Insurance Investments Financial Services Ltd.’s portfolio.Baltimore-washington Financial Advisors boosted its stake in CELG in the latest quarter, The investment management firm added 1,665 additional shares and now holds a total of 29,759 shares of Celgene Corporation which is valued at $3,217,245.
Birchview Capital Lp holds 55.59% of its portfolio in Celgene Corporation for 779,051 shares. (NASDAQ:CELG) opened at 114.01 on Tuesday. Company has a market cap of $86,937 M. For Celgene Corporation (NASDAQ:CELG) total 5 number of trades held during last 3 months and 32 during last 12 months, out of them 0 numbers of buys held in last 3 months and 5 buys in last 12 months.
The average true range of Celgene Corporation’s (CELG) is recorded at 2.28 and the relative strength index of the stock stands 51.16. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.05. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. That would represent a 20.33 per cent year-over-year increase. During the same quarter in the previous year, the company posted $1.23 EPS.
Advertisement
Celgene Corporation is a biopharmaceutical company. Celgene is involved in research in a range of scientific areas created to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
